» Articles » PMID: 38892517

The Evolution in Non-Alcoholic Fatty Liver Disease Patients' Profile and the Associated Sustainable Challenges: A Multidisciplinary Perspective

Overview
Journal Nutrients
Date 2024 Jun 19
PMID 38892517
Authors
Affiliations
Soon will be listed here.
Abstract

The prevalence and incidence of NAFLD is rising due to the obesity pandemic, caused by the widespread availability of ultra-processed foods and the decrease of physical activity. Factors such as socioeconomic status (SES), ethnicity and geographical location are associated with NAFLD, with lower SES correlating with higher incidence, particularly in regions like America or Europe. Beside the quality of food, the quantity also plays a crucial role. The World Health Organization (WHO) recommends a Mediterranean diet with a balanced energy intake. Since no hard medical treatment is available for NAFLD, lifestyle adjustments are key. Patient empowerment by providing relevant information and co-ownership of the therapy will increase the implementation rate and enhance the quality of medical follow-up and medication adherence, as studies report a good adherence to medication among patients who are well-aware of the severity of their disease. Regarding sustainability, patients with NAFLD have a high load of ambulatory follow-up, which, since the COVID-19 pandemic, can be partially provided by teleconsulting. Both patients' lifestyle modifications and healthcare practitioners' therapeutical strategy can decrease the carbon footprint.

Citing Articles

Ultra-Processed Food Consumption and Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD): A Longitudinal and Sustainable Analysis.

Garcia S, Monserrat-Mesquida M, Ugarriza L, Casares M, Gomez C, Mateos D Nutrients. 2025; 17(3).

PMID: 39940330 PMC: 11820933. DOI: 10.3390/nu17030472.


Health condition and socioeconomic status mediate the causal effect of reproductive traits on nonalcoholic fatty liver disease: evidence from Mendelian randomization study.

Wang Q, Wang L, Hao R, Zhang L, Wang W, Xia L Front Endocrinol (Lausanne). 2024; 15:1419964.

PMID: 39280015 PMC: 11393784. DOI: 10.3389/fendo.2024.1419964.


Mesenchymal stem cells: A promising therapeutic avenue for non-alcoholic fatty liver disease.

Cheng C, Hao W, Cheng T World J Stem Cells. 2024; 16(8):780-783.

PMID: 39219724 PMC: 11362857. DOI: 10.4252/wjsc.v16.i8.780.

References
1.
Abenavoli L, Milic N, Peta V, Alfieri F, De Lorenzo A, Bellentani S . Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet. World J Gastroenterol. 2014; 20(45):16831-40. PMC: 4258553. DOI: 10.3748/wjg.v20.i45.16831. View

2.
Younossi Z, Golabi P, Paik J, Henry A, Van Dongen C, Henry L . The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023; 77(4):1335-1347. PMC: 10026948. DOI: 10.1097/HEP.0000000000000004. View

3.
Harris K, Zopey M, Friedman T . Metabolic effects of smoking cessation. Nat Rev Endocrinol. 2016; 12(11):684. DOI: 10.1038/nrendo.2016.171. View

4.
Gao Y, Lu J, Liu X, Liu J, Ma Q, Shi Y . Effect of Long-Term Exercise on Liver Lipid Metabolism in Chinese Patients With NAFLD: A Systematic Review and Meta-Analysis. Front Physiol. 2021; 12:748517. PMC: 8646046. DOI: 10.3389/fphys.2021.748517. View

5.
Monteiro C, Moubarac J, Levy R, Canella D, Louzada M, Cannon G . Household availability of ultra-processed foods and obesity in nineteen European countries. Public Health Nutr. 2017; 21(1):18-26. PMC: 10260838. DOI: 10.1017/S1368980017001379. View